Merck & Co., Inc. MRK
Merck & Co., Inc. (NYSE: MRK) is an oncology drug developer. Its lead program, Keytruda (pembrolizumab), is in Phase 3 for Multiple cancers.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Keytruda / Keytruda Qlex | Multiple cancers | antibody | Approved |
| Gardasil | HPV | vaccine | Approved |
| Winrevair | Pulmonary arterial hypertension | protein/peptide | Approved |
| Welireg | VHL / RCC | small molecule | Approved |
| Capvaxive | Pneumococcal disease | vaccine | Approved |
| MK-1406 | not captured | unclear | Phase 3 |
| V181 | Dengue | vaccine | Phase 3 |
| Tulisokibart | Inflammatory bowel disease | antibody | Phase 3 |
| Sac-TMT | Cancers | antibody | Phase 3 |
Recent results and decisions
- Aug 4, 2026met Phase 2 tulisokibart study in hidradenitis suppurativa met its primary and key secondary endpoints (no figures given); full results at an upcoming meeting.
In hidradenitis suppurativa (HS), the study met its primary and key secondary endpoints. Full results will be shared at an upcoming medical meeting.
Filing - Aug 4, 2026missed Phase 2 tulisokibart study in SSc-ILD did not meet its primary endpoint and will be discontinued; no new safety concerns.
In systemic sclerosis-associated interstitial lung disease (SSc-ILD), the study did not meet its primary endpoint and will be discontinued.
Filing - Apr 30, 2026missed Phase 3 KEYNOTE-975 did not show a statistically significant improvement in event-free survival for Keytruda plus dCRT vs placebo plus dCRT.
In the Phase 3 KEYNOTE-975 study, compared to placebo plus definitive chemoradiotherapy (dCRT), KEYTRUDA plus dCRT did not show a statistically significant improvement in the primary endpoint of EFS in certain patients with locally advanced unresectable esophageal carcinoma.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.